Approval and Access
Access to pre-exposure prophylaxis (PrEP) for people at substantial risk of getting HIV is an essential component of HIV prevention.
People taking PrEP should be provided with access to healthcare and psychosocial and other support services they need to achieve optimal adherence to PrEP, and to promote their health and wellbeing. People should have access to routine medical care, addiction, mental health and sexual health services, harm reduction services and supplies, and housing, shelter and nutrition support services.
There is a pressing need to get HIV antiretroviral medications approved for use as PrEP by people who are HIV-negative but at risk of infection for PrEP, to develop and disseminate practice guidance, and to develop and deliver healthcare provider education.
PrEP treatment literacy and community preparedness campaigns should be implemented for people from specific populations, and psychosocial and other service providers engaged in increasing access to PrEP. Professional development and training about PrEP should be implemented for the full range of health care and psychosocial and other support service providers who need to be engaged in PrEP prescription and adherence support.
Provincial, territorial and federal authorities should put in place mechanisms to ensure that cost is not a barrier to PrEP for people who could benefit from it.
More about PrEP
PrEP stands for pre-exposure prophylaxis. PrEP refers to the use of HIV antiretroviral medications by an HIV-negative person to reduce their risk of getting HIV. PrEP does not prevent other sexually transmitted infections. PrEP is not intended to replace condoms for HIV prevention. The HIV antiretroviral medication Truvada has proven safe and highly effective at preventing HIV-negative people from getting HIV. Truvada is the brand name of the meditation produced by Gilead Sciences; TDF/FTC is the abbreviation for the drug compounds that are combined in Truvada. Large research studies involving men who have sex with women, and men who have sex with men have examined PrEP in controlled conditions and in real world settings. Truvada can reduce by 90% or more the risk of getting HIV when taken every day as prescribed by a doctor, and accompanied by HIV prevention counselling. Truvada is less effective at preventing HIV when doses are missed. PrEP programs can also engage people at substantial risk for HIV in ongoing health care services. PrEP programs include regular testing for HIV and sexually transmitted infections, and referral to HIV care for those who test positive.
Drug approval and public drug plan cost coverage
- Health Canada Notice of Compliance (NOC) (pdf saved here: ( truvada as prep NOC.pdf )
- Product Monograph
- CTAC Patient Group Input submission to the Common Drug Review UPDATED Mar-29-2017
- Common Drug Review (CDEC) Recommendation and reasons UPDATED Mar-29-2017
- Service Provider Guide: Providing HIV PrEP: Steps to Patient Engagement ADDED Mar-30-2017
- Policy Brief 1: Following the Regulatory Pathway for Truvada as PrEP ADDED Mar-29-2017
- Policy Brief 2: Consensus to Action: Next Steps for Equitable Access to PrEP in Canada ADDED Mar-29-2017
- PGI webinar on Truvada as PrEP and slides - http://ctac.ca/resources/videos#PGI
- Presentations and workshops
- CTAC Patient Group Input Submission
- Truvada – CATIE fact sheet
- Pre-exposure prophylaxis (PrEP) – CATIE fact sheet
- CATIE statement on the use of pre-exposure prophylaxis (PrEP) to prevent the sexual transmission of HIV
- ACT PrEP Web page
- Truvada.ca – coming soon!
ADD QUEBEC Réso et mobilise
Social media and online communities
PrEP - Canada: Rethinking HIV Prevention / Repenser la prévention du VIH - https://www.facebook.com/groups/prepcanada/
PrEP Facts: Rethinking HIV Prevention and Sex
Hashtags to follow and use: #PrEP #PrEPCAN #HIVCAN
For more information:
CTAC Policy Researcher